EFFICACY OF THE PAN PI3K-INHIBITOR COPANLISIB COMPARED TO SELECTIVE PI3K-A, -B, -Δ INHIBITORS IN MANTLE CELL LYMPHOMA (MCL)

被引：0
|
作者：
Zoellner, A. [1 ,2 ]
Arnd, J. [3 ]
Hutter, G. [2 ]
Zimmermann, Y. [2 ]
Hiddemann, W. [1 ,2 ]
Dreyling, M. [1 ,2 ]
机构：
[1] Univ Munich, Internal Med Haematol & Oncol 3, Munich, Germany
[2] Clin Cooperat Grp Leukemia, Munich, Germany
[3] Helmholtz Ctr Munich, Cooperat Grp Leukemia 2Clin, Munich, Germany
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1375
引用
收藏
页码：551 / 551
页数：1
相关论文
共 50 条
  • [31] Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor
    Garcia-Valverde, Alfonso
    Rosell, Jordi
    Serna, Garazi
    Valverde, Claudia
    Carles, Joan
    Nuciforo, Paolo
    Fletcher, Jonathan A.
    Arribas, Joaquin
    Politz, Oliver
    Serrano, Cesar
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (06) : 1289 - 1297
  • [32] Synergistic effect of inhibition of multiple PI3K-isoforms due to the differential mode of action of single PI3K-isoform inhibitors in mantle cell lymphoma
    Hutter, G.
    Zimmermann, Y.
    Bamopoulos, S. A.
    Irger, M.
    Hiddemann, W.
    Dreyling, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 154 - 154
  • [33] Putative Roles for PI3K α and δ Isoforms in Refractory Mantle Cell Lymphoma
    Jessen, Katti A.
    Lannutti, Brian J.
    ACTA HAEMATOLOGICA, 2014, 131 (04) : 218 - 219
  • [34] Targeting of PI3K-a and CDK4/6 kinases in mantle cell lymphomas with dual kinase inhibitor ON 123300-lactate
    Akula, Balireddy
    Divakar, Saikrishna A.
    Bharathi, Vijaya E.
    Mallireddigari, Muralidhar R.
    Subbaiah, D. R. C. Venkata
    Pallela, Venkat R.
    Billa, Vinay K.
    Cosenza, Stephen C.
    Reddy, E. Premkumar
    Reddy, M. V. Ramana
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [35] The role of PI3K in modulating NKT cell responses to Mantle Cell Lymphoma
    Shissler, Susannah Claire
    Webb, Tonya J.
    JOURNAL OF IMMUNOLOGY, 2016, 196
  • [36] Activity of pan-FGFR inhibitor rogaratinib and PI3K inhibitor copanlisib in preclinical urothelial bladder cancer models
    Jerchel, Isabel S.
    Lejeune, Pascale
    Lampignano, Rita
    Walter, Alexander
    Lesche, Ralf
    Kamburov, Atanas
    Mumberg, Dominik
    Ellinghaus, Peter
    Politz, Oliver
    Gruenewald, Sylvia
    CANCER RESEARCH, 2019, 79 (13)
  • [37] Selective PI3K and dual PI3K/mTOR inhibitors enhance the efficacy of endocrine therapies in breast cancer models
    Friedman, L.
    Ross, L. B.
    Wallin, J.
    Guan, J.
    Prior, W. W.
    Wu, E.
    Nannini, M.
    Sampath, D.
    CANCER RESEARCH, 2012, 72
  • [38] Buparlisib is a brain penetrable pan-PI3K inhibitor
    Mark C. de Gooijer
    Ping Zhang
    Levi C. M. Buil
    Ceren H. Çitirikkaya
    Nishita Thota
    Jos H. Beijnen
    Olaf van Tellingen
    Scientific Reports, 8
  • [39] Buparlisib is a brain penetrable pan-PI3K inhibitor
    de Gooijer, Mark C.
    Zhang, Ping
    Buil, Levi C. M.
    Citirikkaya, Ceren H.
    Thota, Nishita
    Beijnen, Jos H.
    van Tellingen, Olaf
    SCIENTIFIC REPORTS, 2018, 8
  • [40] Discovery of Potent and Selective PI3Kγ Inhibitors
    Drew, Samuel L.
    Thomas-Tran, Rhiannon
    Beatty, Joel W.
    Fournier, Jeremy
    Lawson, Kenneth, V
    Miles, Dillon H.
    Mata, Guillaume
    Sharif, Ehesan U.
    Yan, Xuelei
    Mailyan, Artur K.
    Ginn, Elaine
    Chen, Jie
    Wong, Kent
    Soni, Divyank
    Dhanota, Puja
    Chen, Pei-Yu
    Shaqfeh, Stefan G.
    Meleza, Cesar
    Pham, Amber T.
    Chen, Ada
    Zhao, Xiaoning
    Banuelos, Jesus
    Jin, Lixia
    Schindler, Ulrike
    Walters, Matthew J.
    Young, Stephen W.
    Walker, Nigel P.
    Leleti, Manmohan Reddy
    Powers, Jay P.
    Jeffrey, Jenna L.
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (19) : 11235 - 11257
12345